We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Elfin Market aims to revolutionize the credit card industry by making credit cards more affordable, fair, and straightforward. They launched the Elfin Card, offering flexible credit that is 50% cheaper than the average credit card, featuring transparent pricing and state-of-the-art iOS and Android apps for real-time account management. The company operates on a flat servicing fee of 2.5% before transferring interest from borrowers to lenders, providing a simpler and more cost-effective credit solution.
days to go: Expired investment: £1,390,059
Core Collective is a luxury boutique fitness destination with a pay as you go model and an immersive and dynamic atmosphere. They provide all the benefits of a personal training session in a small class for a fraction of the cost and offer 7 different classes available for all levels of fitness. 
days to go: Expired investment: £2,056,412
Hungry Tomato is a successful children’s educational publisher that makes fun and illustrated non-fiction children’s books. It has created 170+ successful soft-learning titles, enjoying global interest with 700+ title licenses sold. Hungry Tomato is an established brand, with proven sales in North America. The company's EBITDA is positive for the last 2 yrs with turnover £361,107 EBITDA £98,135 (27%), Dec '18. The funds will be used for growth, for expanding the product range and for launching in the USA.
days to go: Expired investment: £160,830
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.

Pitch Rated

84%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £103,672
WiseAlpha is an investment platform that allow its members the opportunity to invest in secured loan investments from some leading UK companies.  
days to go: Expired investment: £579,150
For Good Causes turn Loyalty points into donations for charities, giving people a new way to give to causes closest to their hearts. Brands are given a while new CSR opportunity and charities are given much-needed funding. Research has shown their is over £7bn unused rewards in the UK, values which could be donated.
days to go: Expired investment: £292,220
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph